5 active not recruiting. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 5 |
Follow Recurrent Melanoma: new trials by email Literature Review of Recurrent Melanoma trials Research Report on Recurrent Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Pembrolizumab, Talimogene Laherparepvec - Advanced Melanoma, Recurrent Melanoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 43 | 2018-06-05 | 2026-05-20 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-26 |
| Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Ipilimumab, Sargramostim - Advanced Melanoma, Metastatic Melanoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 245 | 2010-12-28 | 2026-10-01 |
| Dinaciclib in Treating Patients With Stage IV Melanoma Dinaciclib - Acral Lentiginous Melanoma, Cutaneous Nodular Melanoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 72 | 2009-07-01 | 2026-09-14 |
Melanoma (5) · Glioma (2) · Thyroid Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Ependymoma (1) · Esophageal Neoplasms (1) · Hematologic Neoplasms (1) · Hepatoblastoma (1) · Histiocytosis, Langerhans-Cell (1) · Lung Neoplasms (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Nerve Tissue (5) · Neuroectodermal Tumors (5) · Neuroendocrine Tumors (5) · Nevi and Melanomas (5) · Skin Diseases (5) · Skin Neoplasms (5) · Skin and Connective Tissue Diseases (5) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2)
2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1) · 2C4 antibody (1) · AZD4547 (1) · Ado-Trastuzumab Emtansine (1) · Afatinib (1) · Biopsy (1) · CT-P6 (1) · CTLA-4 Antigen (1) · Colony-Stimulating Factors (1) · Crizotinib (1) · Dasatinib (1) · Disulfides (1) · GSK2636771 (1) · HhAntag691 (1) · Immunoglobulin G (1)
National Cancer Institute (NCI) (5)
United States (5) · Puerto Rico (2) · Guam (1)
Christine A Pratilas (1) · Christopher D Lao (1) · Frank S Hodi (1) · Keith T Flaherty (1) · Siwen Hu-Lieskovan (1)
PMID 25369488, PMID 26586415, PMID 32463741, PMID 33048619, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39342463, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40865033, PMID 41066729, PMID 42853672
U10CA180820 (2), U10CA021115 (1), U10CA032102 (1), U10CA180886 (1), U10CA180888 (1), U24CA196172 (1)